Damora Therapeutics, Inc. (DMRA) Executive Compensation
Damora Therapeutics, Inc. (DMRA) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: DMRA
CIK: 1800315
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
EY Godkendt Revisionspartnerselskab
Auditor SinceSince 12/31/2019 12:00:00 AM
Lead Engagement PartnerHans Vistisen
Audit LocationCopenhagen, Denmark
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-09-28 | 2026-09-25 | 4 | 0001193125-26-403355 | View SEC Doc Filr Page |
| 4 | 2026-08-13 | 2026-08-12 | 4 | 0001193125-26-349537 | View SEC Doc Filr Page |
| 3 | 2026-08-13 | 2026-08-12 | 3 | 0001193125-26-349515 | View SEC Doc Filr Page |
| EFFECT | 2026-08-12 | — | EFFECT Filing | 9999999995-26-002630 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342737 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342730 | View SEC Doc Filr Page |
| POSASR | 2026-08-10 | — | POSASR | 0001193125-26-342717 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342710 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342698 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342687 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342677 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342672 | View SEC Doc Filr Page |
| S-8 POS | 2026-08-10 | — | S-8 POS | 0001193125-26-342663 | View SEC Doc Filr Page |
| POS AM | 2026-08-10 | — | POS AM | 0001193125-26-342562 | View SEC Doc Filr Page |
| 8-A12B/A | 2026-08-10 | — | 8-A12B/A | 0001193125-26-342406 | View SEC Doc Filr Page |
| 10-Q | 2026-08-10 | 2026-06-30 | 10-Q | 0001193125-26-342307 | View SEC Doc Filr Page |
| 144 | 2026-08-06 | — | 144 Filing | 0001970051-26-000018 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-28 | — | SCHEDULE 13G Filing | 0002012383-26-002507 | View SEC Doc Filr Page |
| 8-K | 2026-07-20 | 2026-07-16 | 8-K | 0001193125-26-308899 | View SEC Doc Filr Page |
| 4 | 2026-07-07 | 2026-07-03 | 4 | 0001193125-26-297818 | View SEC Doc Filr Page |
| 144 | 2026-06-22 | — | 144 Filing | 0001970051-26-000017 | View SEC Doc Filr Page |
| 8-K | 2026-06-17 | 2026-04-28 | 8-K | 0001193125-26-274093 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000919574-26-003477 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000902664-26-002524 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0000902664-26-002463 | View SEC Doc Filr Page |